Lynn Kamen
Research Subjects
Lynn Kamen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Srividya Myneni
Genentech Inc
2 shared publicationsBenjamin Ordonia
Genentech Inc
1 shared publicationKai Zheng
Department of Late Stage Pharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080-4990, USA
1 shared publicationShan Chung
Genentech Inc
1 shared publication- Shan Chung
Department of BioAnalytical Sciences, Genentech Inc, South San Francisco, CA, USA
1 shared publication - Tara Thakurta
Department of BioAnalytical Sciences, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080-4990, United States
1 shared publication
Latest Publications
- 4 September 2021
- Published by Springer Nature
- Vol. 2313, 305-312
Method for Measurement of Antibody-Dependent Cellular Phagocytosis
Antibody-based therapeutics are powerful tools to treat disease. While their mechanism of action (MOA) always involves binding to a specific target via the antibody-binding fragment (Fab) region of the antibody, the induction of immune-mediated effector functions through the fragment crystallizable (Fc) region is a vital aspect of antibody therapeutics targeting tumor cells. Cross-linking of the Fc gamma receptors (FcγRs) via cell-bound antibodies activate immune effector cells, leading to antibody-dependent cellular cytotoxicity via natural killer (NK) cells. Linking of FcγRs on macrophages triggers the process of antibody-dependent cellular phagocytosis (ADCP), where antibody-opsonized target cells are internalized in phagosomes and degraded through the process of phagosome maturation and acidification. ADCP activity can be challenging to measure accurately due to the difficulty in differentiating target cells that are bound to a macrophage versus those that are internalized within phagosomes. In this chapter, we describe a protocol that measures ADCP activity by labeling target cells with a pH-sensitive dye that fluoresces brightly in mature phagosomes. The ADCP activity of therapeutics is then measured via flow cytometry. This assay is capable of detecting glycosylation differences arising from manufacturing processes and is suitable for evaluation of ADCP activity of monoclonal antibodies (mAb) to support in vitro biological characterization of drug candidates and lead candidate selection for desirable effector functions.
- 4 September 2021
- Published by Springer Nature
- Vol. 2313, 305-312
Method for Measurement of Antibody-Dependent Cellular Phagocytosis
Antibody-based therapeutics are powerful tools to treat disease. While their mechanism of action (MOA) always involves binding to a specific target via the antibody-binding fragment (Fab) region of the antibody, the induction of immune-mediated effector functions through the fragment crystallizable (Fc) region is a vital aspect of antibody therapeutics targeting tumor cells. Cross-linking of the Fc gamma receptors (FcγRs) via cell-bound antibodies activate immune effector cells, leading to antibody-dependent cellular cytotoxicity via natural killer (NK) cells. Linking of FcγRs on macrophages triggers the process of antibody-dependent cellular phagocytosis (ADCP), where antibody-opsonized target cells are internalized in phagosomes and degraded through the process of phagosome maturation and acidification. ADCP activity can be challenging to measure accurately due to the difficulty in differentiating target cells that are bound to a macrophage versus those that are internalized within phagosomes. In this chapter, we describe a protocol that measures ADCP activity by labeling target cells with a pH-sensitive dye that fluoresces brightly in mature phagosomes. The ADCP activity of therapeutics is then measured via flow cytometry. This assay is capable of detecting glycosylation differences arising from manufacturing processes and is suitable for evaluation of ADCP activity of monoclonal antibodies (mAb) to support in vitro biological characterization of drug candidates and lead candidate selection for desirable effector functions.
- 1 May 2019
- Published by Elsevier in Journal of Immunological Methods
- Vol. 468, 49-54
Development of a kinetic antibody-dependent cellular cytotoxicity assay
- 1 May 2019
- Published by Elsevier in Journal of Immunological Methods
- Vol. 468, 49-54
Development of a kinetic antibody-dependent cellular cytotoxicity assay